Flucytosine adverse reactions

Flucytosine
ANCOBON® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Adverse Reactions

The adverse reactions which have occurred during treatment with Ancobon are grouped according to organ system affected.

• Cardiovascular: Cardiac arrest, myocardial toxicity, ventricular dysfunction.

• Respiratory: Respiratory arrest, chest pain, dyspnea.

• Dermatologic: Rash, pruritus, urticaria, photosensitivity.

• Gastrointestinal: Nausea, emesis, abdominal pain, diarrhea, anorexia, dry mouth, duodenal ulcer, gastrointestinal hemorrhage, acute hepatic injury including hepatic necrosis with possible fatal outcome in debilitated patients, hepatic dysfunction, jaundice, ulcerative colitis, enterocolitis, bilirubin elevation, increased hepatic enzymes.

• Genitourinary: Azotemia, creatinine and BUN elevation, crystalluria, renal failure.

• Hematologic: Anemia, agranulocytosis, aplastic anemia, eosinophilia, leukopenia, pancytopenia, thrombocytopenia, and fatal cases of bone marrow aplasia.

• Neurologic: Ataxia, hearing loss, headache, paresthesia, parkinsonism, peripheral neuropathy, pyrexia, vertigo, sedation, convulsions.

• Psychiatric: Confusion, hallucinations, psychosis.

• Miscellaneous: Fatigue, hypoglycemia, hypokalemia, weakness, allergic reactions, Lyell’s syndrome.

References

Adapted from the FDA Package Insert.